[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600891":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":29,"responsibleParty":50,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":25,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":32,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Second Xiangya Hospital of Central South University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Attapulgite","EXPERIMENTAL","Attapulgite capsules (0.4-0.5 g) were administered at a dose of 3 capsules twice daily for 12 weeks.",[13],"Dietary Supplement: Attapulgite",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Maltodextrin capsules (0.4-0.5 g) were administered at a dose of 3 capsules twice daily for 12 weeks.",[19],"Dietary Supplement: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Participants were administered daily attapulgite (2.5 g) for a duration of 12 weeks.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Participants were administered daily maltodextrin (2.5 g) for a duration of 12 weeks.",[15],[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University","RECRUITING","Changsha","Hunan","410011","China","CN",{"type":39,"coordinates":40},"Point",[41,42],112.97087,28.19874,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Yang Xiao, MD\u002FPhD","CONTACT","86-0731-85292154","xiaoyang29@csu.edu.cn",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Yang Xiao","Associate Professor, Department of Metabolism and Endocrinology, Institute of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Second Xiangya Hospital, Central South University","100600891","efficacy-and-safety-of-attapulgite-in-patients-with-obesity-an-exploratory-clinical-trial-100600891",false,"NCT07103382","Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial","Inclusion Criteria:\n\nObese individuals:\n\n* Aged 18-60 years, regardless of sex\u002Fgender\n* BMI≥28.0kg\u002Fm2\n\nOverweight or obese individuals with type 2 diabetes:\n\n* Aged 18-60 years, regardless of sex\u002Fgender\n* BMI≥24.0kg\u002Fm2\n* HbA1c ≥7.0% and ≤10.0% or the fasting blood glucose ≥7.0 mmol\u002Fl and ≤ 13.3 mmol\u002Fl at screening\n* Stable diabetes treatment for at least 6 months or more\n\nExclusion Criteria:\n\n* Type 1 diabetes, monogenic diabetes, or diabetes due to pancreatic injury or other secondary diabetes\n* Severe diabetic complications within three months before the study initiation, including severe hypoglycemia, diabetic ketoacidosis, or infections\n* Use of weight-affecting products within the past three months or planned use during the study\n* Weight fluctuation \\>5 kg or \\>10% within the past three months\n* Obesity or overweight due to endocrine disorders (such as thyroid dysfunction or Cushing's syndrome)\n* Uncontrolled hypertension, severe cardiac\u002Fhepatic\u002Frenal dysfunction\n* History of gastrointestinal surgery (such as cholecystectomy) within the past year or non-gastrointestinal surgery within six months, or prior bariatric surgery\n* Chronic gastrointestinal disorders (such as recurrent constipation, celiac disease, or food intolerances) or any condition impairing digestion\u002Fabsorption function\n* History of malignant tumors within five years, regardless of whether there is recurrence or metastasis and severe immune dysfunction (such as malignant tumors, HIV\u002FAIDS, immunodeficiency diseases)\n* Use of probiotics, prebiotics, or antibiotics within three months prior to enrollment, or alcohol abuse; Consumption of yogurt within two weeks before the study or during the trial period; History of psychiatric or infectious diseases\n* Pregnancy, lactation, or plans for pregnancy during the study\n* Participation in other clinical trials within the past three months\n* Any condition that in the judgement of the investigator precludes participation","ALL","18 Years","60 Years",{"count":64,"type":65},40,"ESTIMATED","INTERVENTIONAL",[68],"NA","To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight\u002Fobese individuals with type 2 diabetes.",[71],"Obesity",[73,74,75,76],"attapulgite","obesity","placebo-controlled study","randomized controlled trial","2025-08-30",{"date":79,"type":80},"2025-09-05","ACTUAL",{"date":82,"type":80},"2025-06-26",{"date":84,"type":65},"2025-12",{"name":5,"class":6},1]